Literature DB >> 15993456

Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

Brian P Doehle1, Alexandra Schäfer, Bryan R Cullen.   

Abstract

While the human antiretroviral defense factors APOBEC3F and APOBEC3G are potent inhibitors of the replication of HIV-1 mutants lacking a functional vif gene, the Vif protein expressed by wild-type HIV-1 blocks the function of both host cell proteins. Here, we report that a third human protein, APOBEC3B, is able to suppress the infectivity of both Vif-deficient and wild-type HIV-1 with equal efficiency. APOBEC3B, which shows approximately 58% sequence identity to both APOBEC3F and APOBEC3G, shares the ability of these other human proteins to bind the nucleocapsid domain of HIV-1 Gag specifically and to thereby package into progeny virion particles. However, APOBEC3B differs from APOBEC3F and APOBEC3G in that it is unable to bind to HIV-1 Vif in co-expressing cells and is therefore efficiently packaged into HIV-1 virions regardless of Vif expression. Unfortunately, APOBEC3B also differs from APOBEC3F and APOBEC3G in that it is not normally expressed in the lymphoid cells that serve as targets for HIV-1 infection. These studies therefore raise the possibility that activation of the endogenous APOBEC3B gene in primary human lymphoid cells could form a novel and effective strategy for inhibition of HIV-1 replication in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993456     DOI: 10.1016/j.virol.2005.06.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  124 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.

Authors:  Xiaojun Wang; Aierken Abudu; Sungmo Son; Ying Dang; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

4.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

6.  Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Roderick W Davis; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

7.  Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.

Authors:  Xiaojun Wang; Patrick T Dolan; Ying Dang; Yong-Hui Zheng
Journal:  J Biol Chem       Date:  2006-12-01       Impact factor: 5.157

Review 8.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

9.  Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.

Authors:  Hal P Bogerd; Heather L Wiegand; Amy E Hulme; José L Garcia-Perez; K Sue O'Shea; John V Moran; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-25       Impact factor: 11.205

10.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.